Prostate CancerMar 15, 2026
A diagnosis of stage 4 prostate cancer means the cancer has moved beyond the prostate itself, into lymph nodes, bones, or other organs. That sounds like a single category, but it's not. The research makes clear that "stage IV" covers a surprisingly wide spectrum, from tumors pressing into nearby structures to cancer that has reached the liver. Where it has spread matters enormously, and so does how it's treated. The old approach of using hormone therapy alone has been replaced by layered combinations that are meaningfully extending survival.
The most practical thing to understand: not all stage 4 prostate cancer behaves the same way, treatment has shifted dramatically in the last decade, and the specifics of your situation drive what comes next far more than the stage number alone.
Prostate CancerMar 15, 2026
When people think of prostate cancer, they usually associate it with men. This is because the prostate is a small gland found in individuals assigned male at birth. Its primary role is to produce seminal fluid that nourishes and transports sperm. However, the question of whether women can get prostate cancer is still more complex than it may appear.
Prostate CancerMar 15, 2026
Prostate cancer is the most common cancer in men and the second leading cause of cancer death worldwide. Nearly one in six men will face a diagnosis during their lifetime, and in the United States alone, hundreds of thousands of men are diagnosed each year. The disease often develops silently, with no symptoms until it has advanced, which makes screening especially important.
As Prostate Cancer Awareness Month nears its end, it's important to highlight the tests that make the greatest impact on early detection. While most doctors still rely on total PSA, clinical research shows that free PSA delivers stronger predictive value by distinguishing cancer from benign conditions and reducing unnecessary biopsies.
Prostate CancerMar 15, 2026
For decades, the standard way to obtain a tissue diagnosis has been the transrectal ultrasound-guided biopsy. This method is simple and widely available, but it introduces risks of infection and often struggles to detect tumors located in the anterior and apical regions of the prostate. In recent years, the transperineal approach has re-emerged as a safer and in many cases more effective alternative. By passing the biopsy needle through the perineal skin rather than the rectum, this method reduces infectious complications and allows better access to areas of the prostate that are otherwise undersampled.
Prostate CancerMar 15, 2026
For men preparing for a prostate biopsy, it is natural to focus on the procedure itself. Yet the real challenge often begins afterward, when patients must navigate healing, manage side effects, and regain confidence in their daily lives. Recovery is not only about easing pain and controlling bleeding. It also involves restoring continence, protecting sexual health, and regaining psychological well-being. Fortunately, clinical research offers clear insights into what factors can help men recover more quickly and effectively.
Prostate CancerMar 15, 2026
Prostate cancer is one of the most commonly diagnosed cancers among men, especially those over the age of 50. Early detection significantly improves treatment outcomes, but many men are unsure how to monitor their prostate health without visiting a doctor. While a confirmed diagnosis always requires medical evaluation, several at-home tools and awareness strategies can help men recognize early warning signs and decide when to seek professional attention.
Prostate CancerMar 15, 2026
Prostate cancer remains one of the most common cancers among men worldwide. Early detection is key to ensuring favorable outcomes, yet screening has long been a challenge. For decades, the total prostate-specific antigen (PSA) test has been used to help detect possible prostate malignancy. However, total PSA is an imperfect biomarker. Many men with elevated PSA do not have cancer, while others with prostate cancer may show PSA levels that fall in the diagnostic “gray zone.”
To refine detection, researchers have studied variations of PSA, particularly the proportion of PSA that circulates freely in the bloodstream compared to PSA bound to proteins. This measurement, known as the free-to-total PSA ratio, or simply percent free PSA, has been investigated as a way to improve specificity.
Prostate CancerMar 15, 2026
Prostate cancer is one of the most common cancers in men worldwide. In early stages, it often causes no symptoms and can be highly treatable, with survival rates exceeding 99%. However, when the disease progresses to an advanced or metastatic stage, survival rates drop sharply. Research using the National Cancer Database found that five-year survival for distant disease is less than 31%, compared to nearly universal survival for localized disease.
Late-stage or terminal prostate cancer refers to disease that has spread beyond the prostate, often to bones, lymph nodes, or other organs, and is no longer responsive to curative treatment. For men in the final months of life from prostate cancer, the illness is typically widespread, and symptoms result both from the tumor itself and from complications in vital organs. Understanding these signs can help patients and families prepare, seek appropriate medical attention, and access palliative care early.
Prostate CancerMar 15, 2026
For many men, hearing that they need a prostate biopsy brings an immediate sense of unease. The idea of a needle sampling tissue from such a sensitive organ raises questions not only about pain and recovery but also about long-term harm. This article examines whether a biopsy damages the prostate, drawing from clinical research. We will explore what happens during a biopsy, the short-term and long-term effects on the gland, the risks of infection and inflammation, and the impact on urinary and sexual health.
Prostate CancerMar 15, 2026
Stage 4 prostate cancer, also called metastatic prostate cancer, represents the most advanced stage of the disease. At this point, cancer has spread beyond the prostate gland to distant organs or bones. In clinical terms, this is often labeled as M1 disease under the TNM classification system.
Historically, the prognosis for patients with stage 4 prostate cancer has been poor, with median survival times ranging from two to three years after diagnosis. However, advances in treatment such as androgen deprivation therapy (ADT), chemotherapy, targeted therapy, and immunotherapy have made it possible for some individuals to live far longer than previously thought.
Prostate CancerMar 15, 2026
Prostate cancer remains one of the most common cancers affecting men globally, and accurate prediction of prognosis is critical for guiding treatment choices. Among the tools available, the Gleason scoring system has stood the test of time as one of the strongest predictors of disease behavior. This system assigns a score to prostate tumors based on microscopic patterns, where lower numbers reflect well-differentiated, less aggressive tissue and higher numbers indicate more disorganized, aggressive tumors.
When two different architectural patterns are present, the most common pattern is listed first, followed by the second most common. The sum of these two patterns forms the Gleason score. A Gleason score of 3+4 equals 7, which places it into what is commonly referred to as “favorable intermediate-risk” prostate cancer. It differs meaningfully from Gleason score 4+3, even though both add to 7. The order reflects which pattern dominates and has strong implications for prognosis.
TestosteroneMar 15, 2026
High dihydrotestosterone (DHT) levels are often blamed for prostate cancer, cardiovascular disease, and hair loss. But most research shows that high DHT is rarely dangerous for men. It can cause hair and skin changes and increase red blood cell production, but prostate and cardiovascular risks remain low. In women, however, elevated DHT can disrupt fertility and trigger PCOS-like symptoms.
Prostate CancerMar 13, 2026
Eligard, an injectable form of leuprolide acetate, pushes testosterone down to castrate levels in the vast majority of men with prostate cancer. But "vast majority" ranges from 94% to 98% with shorter dosing intervals, dropping to roughly 88–90% with the longest option. That gap is worth understanding if you or someone you care about is choosing between a shot every month versus every six months.
Eligard works as a GnRH agonist (gonadotropin-releasing hormone agonist), which essentially tricks the brain's hormonal signaling system into shutting down testosterone production. It uses a polymer gel called Atrigel that forms a small biodegradable implant under the skin, slowly releasing leuprolide over weeks or months depending on the formulation.
